NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ — AbbVie (NYSE:
Read more
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
PRINCETON, N.J.–(BUSINESS WIRE)– September 12, 2018 — Bristol-Myers Squibb Company
Read moreEisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) —
Read moremiRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) — miRagen Therapeutics,
Read moreAclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics,
Read moreAllergan’s Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
DUBLIN, June 11, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN),
Read moreParatek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
BOSTON, June 11, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc.
Read more